Sorry, you need to enable JavaScript to visit this website.

Skip to main content


Infectious Disease Treatment Development


Infectious Diseases & Vaccines

Infectious Diseases & Vaccines

The structure of HIV
The structure of HIV

As we go from strength to strength, we aim to extend our impact with meaningful innovations.

The Janssen Infectious Diseases & Vaccines multidisciplinary development team, including physicians, virologists, toxicologists, statisticians, data managers, experts in chemistry and pharmaceutics, regulatory experts and project managers among others, is dedicated to the rapid development of transformational medicines and vaccines.

Our development process is marked by a close-knit collaboration between the members of each function to ensure the best possible prospects for new and fledgling medical solutions. Highly qualified professionals with a sense of urgency and care for detail keep us focused on addressing the needs of people today and tomorrow. This approach has yielded the approval of six transformational medicines in the areas of human immunodeficiency virus (HIV) and hepatitis C in less than a decade.

As we go from strength to strength, we aim to extend our impact with meaningful innovations in the areas of respiratory syncytial virus (RSV), influenza and extra-intestinal pathogenic Escherichia coli (ExPEC) among others, while maintaining our commitment in combatting HIV and hepatitis C. This includes bringing together the best science from around the globe to address these significant unmet needs. The acquisition of Alios BioPharma in late 2014 reflects this commitment. Together we will further strengthen Janssen’s infectious diseases pipeline to address the needs of patients and families affected by some of the world’s most devastating diseases, in the near term for RSV.

With a platform of nucleotide analog polymerase inhibitors as a result of the acquisition, we are further committed to combating hepatitis C by exploring the potential of multiple treatment combinations to make a difference in patients' lives.

HIV remains a significant medical challenge. We remain committed to pursuing a shift in the HIV treatment paradigm and are collaborating with several partners to develop new HIV treatments and fixed-dose regimens.